The short version of systematic review fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-30 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
== Characteristics == Changes, mostly seen as advances, in all areas of human activity—politics, industry, society, economics, commerce, transport, communication, mechanization, automation, science, medicine, technology, religion, the arts, and other aspects of culture—appear to have transformed an Old World into the Modern or New World. In each case, the identification of the change over time can be used to demarcate the old and old-fashioned from the modern. Starting in western countries, the modern world has seen a systematic re-evaluation of value systems, monarchical regimes, and feudal economic systems. These have often been replaced by democratic and liberal ideas in the areas of politics, science, psychology, sociology, and economics. Some events of modern history, though born out of context not entirely new, show a new way of perceiving the world. The concept of modernity interprets the general meaning of these events and seeks explanations for major developments. Historians analyze the events taking place in Modern Times, since the so-called "Middle Ages" (between Modern and Ancient Times).
=== 1: Channels/pores === α-helical protein channels such as voltage-gated ion channel (VIC), ligand-gated ion channels(LGICs) β-barrel porins such as aquaporin channel-forming toxins, including colicins, diphtheria toxin, and others Nonribosomally synthesized channels such as gramicidin Holins; which function in export of enzymes that digest bacterial cell walls in an early step of cell lysis. Facilitated diffusion occurs in and out of the cell membrane via channels/pores and carriers/porters. Note:
The half-life, t1/2, is the time taken for the activity of a given amount of a radioactive substance to decay to half of its initial value. The decay constant, λ "lambda", the reciprocal of the mean lifetime (in s−1), sometimes referred to as simply decay rate. The mean lifetime, τ "tau", the average lifetime (1/e life) of a radioactive particle before decay. Although these are constants, they are associated with the statistical behavior of populations of atoms. In consequence, predictions using these constants are less accurate for minuscule samples of atoms. In principle a half-life, a third-life, or even a (1/√2)-life, could be used in exactly the same way as half-life; but the mean life and half-life t1/2 have been adopted as standard times associated with exponential decay. Those parameters can be related to the following time-dependent parameters:
Polyethyleneglycols are used in perfumes, cosmetics, pharmaceuticals, lubricants, paint thinners, and plasticizers. Ethylene glycol ethers are part of brake fluids, detergents, solvents, lacquers, and paints. Ethanolamines are used in the manufacture of soap and detergents and for purification of natural gas. Ethoxylates are reaction products of ethylene oxide with higher alcohols, acids, or amines. They are used in the manufacture of detergents, surfactants, emulsifiers, and dispersants. Whereas synthesis of ethylene glycols is the major application of ethylene oxide, its percentage varies greatly depending on the region: from 44% in the Western Europe, 63% in Japan, and 73% in North America to 90% in the rest of Asia, and 99% in Africa.
Sources: en.wikipedia.org
Shaka was the illegitimate son of Senzangakhona, Chief of the Zulus. He was born c. 1787. He and his mother, Nandi, were exiled by Senzangakhona, and found refuge with the Mthethwa. Shaka fought as a warrior under Dingiswayo, leader of the Mthethwa Paramountcy. When Senzangakona died, Dingiswayo helped Shaka become king of the Zulu. After Dingiswayo's death at the hands of Zwide, king of the Ndwandwe, around 1816, Shaka assumed leadership of the entire Mthethwa alliance. Shaka expanded the Zulu Kingdom through war and diplomacy. Shaka's clan at first numbered no more than a few thousands, but eventually grew in size to 45,000 after absorbing neighbouring clans. His military reforms included new battle techniques, training, and tough discipline, as well as the replacement of long throwing spears in exchange for the more effective short stabbing spears. Conscripted men were segregated from the rest of Zulu society to be trained as an organised standing army called the amabutho. The alliance under his leadership survived Zwide's first assault at the Battle of Gqokli Hill (1818). Within two years, Shaka had defeated Zwide at the Battle of Mhlatuze River (1820) and broken up the Ndwandwe alliance. The Ngoni people fled as far north as Tanzania and Malawi. By 1822, Shaka had conquered an empire covering an area of around 80,000 square miles (210,000 km2), covering Pongola to the Tugera Rivers.
== Design == Adam Foster, Minerva's designer, is critical of Valve's design of Half-Life 2 maps. His belief is that game developers focus on creating gameplay friendly environments that do not work in an architectural way, "a series of unconnected boxes" says Foster, Minerva's environments are built as actual environments (with correctly proportioned structures and areas) with gameplay worked in later. This creates a more open design, in which players may, in places, navigate in multiple ways. Later locations can be seen in earlier stages of the game (along corridors or through windows for example). Map design is the mod's hallmark. While all levels are constructed primarily using Valve's resources, with few new models or textures, Foster follows his own design ideals – that of compact, well designed maps. Although the levels seem huge, as play unfolds, they are in fact very small - wrapping around to use the least space possible. This creates a sense of realism. As pointed out by Planet Half-Life: "Instead of relying on horizontally-sprawling, immense maps that stress the engine's area-capabilities to its max, Minerva maps are incredibly small. This is because of Foster's ground-breaking idea to utilize every possible area to its maximum potential, and instead of expanding horizontally, he expands vertically." As a result, Minerva maps have a much shorter load time than maps in the original game. Foster creates the maps in layers.
Methods similar to those first developed by Roselius have continued to dominate, and are sometimes known as the direct organic solvent method. However, because of health concerns regarding benzene (which is recognized today as a carcinogen), other solvents, such as dichloromethane or ethyl acetate, are now used. The unroasted (green) beans are first steamed and then rinsed with the solvent which extracts the caffeine, while leaving other constituents largely unaffected. The process is repeated between 8 and 12 times until the caffeine content meets the required standard (97% of caffeine removed according to the US standard, or 99.9% caffeine-free by mass per the EU standard).
It was demonstrated, that muscle cells, that lack AMPD1, stock and consume significantly more glutamate, and produce more alanine in this state, compared to healthy controls, which indicates occurrence of a higher concentration of pyruvate in the cell during exercise. The pool of AMP also grows bigger than in the controls, which would cause higher rate of glucose liberation from glycogen. This state can last for as long as glycogen is available, and can be prolonged by constantly eating carbohydrate-rich food. If the load on muscles is greater than the body's ability to recycle lactate back into glucose, lactate will start to build up in the blood. Once lactate reaches its renal re-absorption threshold (5–6 mmol/L in general population), it gets lost to urine, wasting many calories (and producing bright matte yellow particles on surfaces where urine dries). At about the same time the kidney will also start correcting blood acidity by acidifying urine. Overly acidic urine causes irritation that feels like a frequent urge to urinate (with little volume) and a "hot" urine. In order to excrete lactate, kidney must also excrete magnesium as an obligatory cation, which may lead to acute and chronic magnesium deficiency. Supplementary magnesium in the form of lactate or citrate may be rapidly lost in the same way. Because magnesium is essential to aerobic metabolism, over time, magnesium loss may lead to a vicious cycle, where the citric acid cycle is further down-regulated, lactate production is increased, and magnesium loss is increased again.
It sought, and got, the king's acceptance to have an Irish minister, to the complete exclusion of British ministers, formally advise the king in the exercise of his powers and functions as king in the Free State. This gave the President of the Executive Council the right to directly advise the king in his capacity as His Majesty's Irish Prime Minister. Two examples of this are the signing of a treaty between the Free State and the Portuguese Republic in 1931, and the act recognising the abdication of King Edward VIII in 1936 separately from the recognition by the British Parliament. The unprecedented replacement of the use of the Great Seal of the Realm and its replacement by the Great Seal of Saorstát Éireann, which the king awarded to the Free State in 1931. (The Irish Seal consisted of a picture of King George V enthroned on one side, with the Irish state harp and the words Saorstát Éireann on the reverse. It is now on display in the Irish National Museum, Collins Barracks, Dublin.) When Éamon de Valera became President of the Executive Council (prime minister) in 1932 he described Cosgrave's ministers' achievements simply. Having read the files, he told his son, Vivion, "they were magnificent, son". The Statute of Westminster allowed de Valera, on becoming President of the Executive Council (February 1932), to go even further.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.